Evidence map›Paper›PMID 41155964›Full record

ArticlePharmaceutics2025

Engineered Liposomal Delivery of

Yue Shen, Richard Nii Lante Lamptey, Gowthami Reddy Mareddy, Bivek Chaulagain, Jagdish Singh, Chengwen Sun

Abstract read
In one paragraph

Article in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yue ShenDepartment of Pharmaceutical Sciences, North Dakota State University, Fargo, ND 58105, USA.
Richard Nii Lante LampteyDepartment of Pharmaceutical Sciences, North Dakota State University, Fargo, ND 58105, USA.ORCID 0000-0002-9659-9083
Gowthami Reddy MareddyDepartment of Pharmaceutical Sciences, North Dakota State University, Fargo, ND 58105, USA.ORCID 0000-0003-3183-3200
Bivek ChaulagainDepartment of Pharmaceutical Sciences, North Dakota State University, Fargo, ND 58105, USA.
Jagdish SinghDepartment of Pharmaceutical Sciences, North Dakota State University, Fargo, ND 58105, USA.
Chengwen SunDepartment of Pharmaceutical Sciences, North Dakota State University, Fargo, ND 58105, USA.ORCID 0000-0001-5889-8448

Funding

Enhanced APOE2 Expression into Brain for Therapeutic Strategy for Alzheimer's DiseaseRF1AG068034 · NIA · NORTH DAKOTA STATE UNIVERSITY · PI KANEKIYO, TAKAHISA, SINGH, JAGDISH · 2021 to 2022
$1.6M
Enhanced APOE2 Expression into Brain for Therapeutic Strategy for Alzheimer's DiseaseR01AG068034 · NIA · NORTH DAKOTA STATE UNIVERSITY · PI KANEKIYO, TAKAHISA, SINGH, JAGDISH · 2024 to 2025
$1.0M
Regulation of Cerebral Arteries by Apelin/APJ Receptor MechanismsR15HL124338 · NHLBI · NORTH DAKOTA STATE UNIVERSITY · PI SUN, CHENGWEN · 2015 to 2020
$870k
Treatment of Neurogenic Hypertension by Delivery of ACE2 across the BBBR15HL143519 · NHLBI · NORTH DAKOTA STATE UNIVERSITY · PI SUN, CHENGWEN · 2018 to 2018
$435k
National Heart, Lung, and Blood Institute (NHLBI) 2R15HL124338-02A1, 1R15HL143519-01National Institute of Aging of National Institutes of Health RF1 AG068034, RF1 AG068034-01S1, and R01 AG068034-02NHLBI NIH HHS R15 HL124338NHLBI NIH HHS R15 HL143519NIA NIH HHS R01 AG068034NIA NIH HHS RF1 AG068034
6 · The paper itself

Abstract

The blood-brain barrier (BBB) restricts the entry of therapeutic agents into the brain cardiovascular regulatory region, potentially contributing to drug-resistant hypertension.

Indexed as

angiotensin-converting enzyme 2blood–brain barrierbrain-targeted deliveryfunctionalized liposomesneurogenic hypertension

Identifiers

PMID41155964
PMCPMC12566711

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.